ARIAD Pharmaceuticals, Inc.ARIA
and Newcastle University, U.K., on behalf of the U.K. National Cancer Research Institute (NCRI) CML Working Group, today announced an agreement to collaborate on a multicenter, randomized Phase 3 trial, named SPIRIT 3, to assess the impact of switching patients with chronic myeloid leukemia (CML) being treated with a first-line tyrosine kinase inhibitor, upon suboptimal response or treatment failure, to ponatinib. The NCRI expects to begin enrollment in the trial of 1,000 patients at approximately 172 clinical research sites in the U.K. in the second quarter of 2013. “The SPIRIT 3 study was designed in partnership with ARIAD to provide the scientific community and patients living with chronic-phaseSee full press release
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.